BioCentury | Mar 24, 2017
Clinical News

HT-100 regulatory update

...to have 3 DMD compounds, including HT-100, in the clinic this year. The second compound, DT-200...
BioCentury | Mar 22, 2017
Clinical News

Akashi restarting development of DMD candidate

...to have three DMD compounds, including HT-100, in the clinic this year. The second compound, DT-200...
BioCentury | Jun 3, 2013
Product Development

The DMD landscape

...Dart is also pursuing a strategy to increase muscle strength in DMD patients. DT-200 (formerly GLPG0492...
...in healthy volunteers were insufficient to pursue further development for that indication. But Williams said DT-200...
...of salicylate and docosahexaenoic acid (DHA) Ph I Dart Therapeutics Inc./ Galapagos N.V. (Euronext:GLPG; Pink:GLPYY) DT-200...
BioCentury | Mar 25, 2013
Company News

Dart Therapeutics, Galapagos deal

...Dart said it is developing DT-200 (formerly GLPG0492 ), which it obtained from Galapagos, for Duchenne...
...pursue further development in the indication. Dart said it will begin Phase IIa testing of DT-200...
BioCentury | Apr 30, 2012
Clinical News

GLPG0492: Development discontinued

...Galapagos discontinued development of GLPG0492 to treat cachexia. The company said data from a Phase I...
...in preclinical testing for Duchenne muscular dystrophy (DMD). Galapagos N.V. (Euronext:GLPG; Pink:GLPYY), Mechelen, Belgium Product: GLPG0492...
BioCentury | Jul 25, 2011
Clinical News

GLPG0492: Phase I started

...GLPG0492 for 2 weeks in >=24 healthy volunteers. Galapagos N.V. (Euronext:GLPG; Pink:GLPYY), Mechelen, Belgium Product: GLPG0492...
BioCentury | Apr 16, 2011
Clinical News

Galapagos falls after stopping RA trial

...II testing this year: GLPG0634 , a Janus kinase-1 (JAK-1) and JAK-2 inhibitor for RA; GLPG0492...
BioCentury | Dec 13, 2010
Clinical News

GLPG0492: Phase I data

...I trial in 16 young healthy volunteers showed that single doses of 0.5-120 mg oral GLPG0492...
...serious adverse events or changes in vital signs or laboratory parameters. Galapagos also said that GLPG0492...
...trial of GLPG0492 in healthy volunteers next year. Galapagos N.V. (Euronext:GLPG; Pink:GLPYY), Mechelen, Belgium Product: GLPG0492...
BioCentury | Sep 9, 2010
Targets & Mechanisms

Muscling up in cancer cachexia

...in human reproduction and fertility, including the testosterone and follicle stimulating hormone (FSH) pathways. Galapagos' GLPG0492...
BioCentury | Jun 17, 2010
Targets & Mechanisms

Hormone attack on AD

...Co. Inc. , which is in Phase IIb testing for cancer cachexia, Galapagos N.V. 's GLPG0492...
Items per page:
1 - 10 of 16